Form 4: Crinetics Pharmaceuticals CSO Exercises Options and Sells Shares Under Pre-Arranged Plan

Crinetics Pharmaceuticals' Chief Scientific Officer, Stephen F. Betz, reported the exercise of stock options and subsequent sale of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• Stephen F. Betz, Chief Scientific Officer of Crinetics Pharmaceuticals, Inc. (CRNX), reported transactions on June 12, 2025.
• Mr. Betz acquired 71,525 shares of Common Stock by exercising stock options at an exercise price of $1.91 per share.
• He also acquired an additional 16,645 shares of Common Stock by exercising stock options at an exercise price of $9.28 per share.
• A total of 97,483 shares of Common Stock were disposed of through open market sales at a volume-weighted average price of $32.23 per share, with sales prices ranging from $31.67 to $32.65 per share.
• The sale was executed automatically pursuant to a Rule 10b5-1 trading plan adopted by Mr. Betz.
• Following these transactions, Mr. Betz beneficially owns 99,713 shares of Common Stock.
• His beneficial ownership of stock options stands at 108,514 options with an exercise price of $1.91 and 58,198 options with an exercise price of $9.28.
• The reported common stock ownership includes 438 shares acquired under the Issuer's Employee Stock Purchase Plan.

Sentiment

Score: 6

Explanation: The filing reports a routine insider transaction involving the exercise of stock options and subsequent sale of shares under a pre-arranged 10b5-1 plan. The officer realized significant gains, which is a positive for the individual, and the pre-planned nature mitigates any negative sentiment typically associated with insider selling, making the overall sentiment neutral to slightly positive.

Positives

• The Chief Scientific Officer realized significant gains from the exercise of stock options and subsequent sale of shares, as the sale price of $32.23 per share is substantially higher than the option exercise prices of $1.91 and $9.28.
• The transaction was conducted under a Rule 10b5-1 trading plan, indicating a pre-arranged and systematic approach to stock sales, which often mitigates concerns about opportunistic insider selling.

Negatives

• The sale of 97,483 shares by a key executive, even if pre-planned, represents a reduction in their direct equity exposure to the company, which some investors might view cautiously.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: The transaction is a routine insider filing and does not directly impact the company's operational or strategic direction. It reflects a liquidity event for a key executive.
• Employees: The inclusion of shares acquired under the Employee Stock Purchase Plan (ESPP) indicates ongoing employee participation in the company's equity programs.

Key Dates

Keywords

Crinetics Pharmaceuticals, CRNX, Form 4, Insider Transaction, Stock Options, Beneficial Ownership, Rule 10b5-1, Executive Compensation, Stock Sale